Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citigroup Inc. (C) vs Quest Diagnostics Inc (DGX) Price & Performance

Citigroup Inc.Trade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs Quest Diagnostics Inc — how do they compare? Citigroup Inc. trades at $137.68 (market cap $227.75B), while Quest Diagnostics Inc trades at $237.5 (market cap $26.21B). The key difference: Citigroup Inc. is far larger — about 8.7× Quest Diagnostics Inc's market cap, and Citigroup Inc. pays the higher dividend (1.97%). Which is the better fit depends on your goals.

CDGX
Market Cap
$227.75B$26.21B
Sector
FinancialsHealth
52-Week High
$145.67$238.50
52-Week Low
$92.59$173.49
Dividend Yield
1.97%1.45%
Enterprise Value
$31.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $137.78, up 1.89% today, with a bullish technical signal from moving averages and a consensus analyst price target of $154.38. Recent Q2 2026 earnings beat expectations with EPS of $3.15 versus $2.72 expected, while revenue reached a decade high. The company is actively hiring senior bankers and launching digital trade solutions, signaling strategic growth initiatives.

The outlook is positive, supported by earnings momentum and a 59% analyst buy rating, but risks include volatile cash flows from operations and high leverage. The stock offers potential upside to the price target, with investor focus on execution of the medium-term ROTCE target of 14-15%.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.

The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

Read more on C

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX